Valuation : ImmuCell Corporation

Market Cap 90.82M 78.14M 73.33M 67.09M 125M 8.59B 126M 867M 338M 4.39B 341M 334M 14.13B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 100M 86.22M 80.91M 74.03M 138M 9.47B 139M 957M 373M 4.84B 376M 368M 15.59B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.82%
Yield 2024 *
-
Yield 2025 -
1 day-0.15%
1 week-0.20%
Current month+2.15%
1 month-9.42%
3 months-0.50%
6 months+56.25%
Current year+62.60%
1 week 9.77
Extreme 9.77
10.3
1 month 9.55
Extreme 9.55
11.38
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-10-31
Director of Finance/CFO 47 2025-04-06
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 2013-11-30
Director/Board Member 61 2014-03-30
Director/Board Member 66 2020-06-09
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Free

Chairman

11,933 0.1319%
4/15/26 Free

Director

17,899 0.1979%
4/15/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.20%+53.23%+113.68% 90.82M
-0.17%-1.33%+57.27%+107.89% 1,034B
+1.03%+4.55%+56.10%+72.93% 663B
-0.30%+1.08%+23.17%+78.61% 462B
+2.09%-2.06%+32.28%+38.37% 344B
0.00%+5.36%+27.40%+47.50% 307B
+1.42%+0.26%-0.52%+13.62% 251B
+0.16%+1.54%+56.32%+74.69% 239B
-0.03%+2.13%-17.30%-53.99% 207B
+0.84%+1.07%+33.15%+100.17% 186B
Average +0.64%-0.65%+32.11%+59.35% 369.35B
Weighted average by Cap. +0.58%-0.84%+38.60%+68.44%

Financials

2024 2025
Net sales 26.49M 22.79M 21.39M 19.57M 36.53M 2.5B 36.82M 253M 98.55M 1.28B 99.49M 97.32M 4.12B 27.64M 23.79M 22.32M 20.42M 38.12M 2.61B 38.42M 264M 103M 1.34B 104M 102M 4.3B
Net income -2.16M -1.86M -1.74M -1.59M -2.97M -204M -3M -20.6M -8.02M -104M -8.1M -7.92M -336M -1.04M -895K -840K -768K -1.43M -98.31M -1.45M -9.93M -3.87M -50.24M -3.91M -3.82M -162M
Net Debt 11.34M 9.76M 9.16M 8.38M 15.64M 1.07B 15.76M 108M 42.19M 548M 42.59M 41.66M 1.76B 9.39M 8.08M 7.58M 6.93M 12.94M 887M 13.05M 89.66M 34.92M 454M 35.25M 34.48M 1.46B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
26-09-03 US$10.00 0.00% 8,873
26-09-02 US$10.00 +0.81% 16,278
26-09-01 US$9.920 +1.33% 6,992
26-08-31 US$9.790 -1.51% 20,133
26-08-28 US$9.940 -0.80% 5,607
  1. Stock Market
  2. Stocks
  3. ICCC Stock